Filtered By:
Source: Clinical Cardiology

This page shows you your search results in order of relevance. This is page number 3.

Order by Relevance | Date

Total 111 results found since Jan 2013.

Association between ideal cardiovascular health metrics and risk of cardiovascular events or mortality: A meta ‐analysis of prospective studies
ConclusionsIdeal CVH status, or even 1 point increase in CVH metrics, can result in substantial reductions in the risk of CVD, stroke, and mortality. Improving metrics of smoking, diet, physical activity, plasma glucose levels, and blood pressure will achieve the highest benefits.
Source: Clinical Cardiology - November 1, 2017 Category: Cardiology Authors: Leilei Guo, Shangshu Zhang Tags: CLINICAL INVESTIGATIONS Source Type: research

Septal Alcohol Ablation Versus Myectomy for Symptomatic Hypertrophic Obstructive Cardiomyopathy: Systematic Review and Meta ‐analysis
ConclusionCompared with SM, ASA is associated with lower peri ‐procedural mortality and stroke but higher rates of pacemaker implantations and re‐intervention. However, there was no difference between ASA and SM with regards to long‐term all‐cause mortality, cardiovascular mortality or SCD.This article is protected by copyright. All rights reserved.
Source: Clinical Cardiology - November 12, 2018 Category: Cardiology Authors: Mohammed Osman, Babikir Kheiri, Khansa Osman, Mahmoud Barbarawi, Hani Alhamoud, Fahad Alqahtani, Mohamad Alkhouli Tags: REVIEW Source Type: research

Guideline Adherence of Antithrombotic Treatment Initiated by General Practitioners in Patients With Nonvalvular Atrial Fibrillation: A Danish Survey
ConclusionsAntithrombotic treatment of AF patients is in general well performed in primary care in Denmark. Further improvements may be achieved by thorough stroke risk stratification on the basis of current evidence‐based guidelines.
Source: Clinical Cardiology - May 13, 2013 Category: Cardiology Authors: Axel Brandes, Mikkel Overgaard, Liane Plauborg, Christian Dehlendorff, Frede Lyck, Jørgen Peulicke, Søren Vinther Poulsen, Steen Husted Tags: Clinical Investigation Source Type: research

New Antithrombotics for Secondary Prevention of Acute Coronary Syndrome
This study was terminated early in patients with prior stroke owing to excess ICH, though an increased risk of ICH or fatal bleeding was not detected in patients with prior myocardial infarction. The Apixaban for Prevention of Acute Ischemic and Safety Events 2 (APPRAISE‐2) trial of standard‐dose apixaban added to standard care in patients with ACS was also stopped early owing to excess serious bleeding. However, in Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Patients With Acute Coronary Syndromes (ATLAS ACS 2 TIMI 51), fatal bleeding or fatal ICH did not increase with low‐do...
Source: Clinical Cardiology - January 22, 2014 Category: Cardiology Authors: Shinya Goto, Aiko Tomita Tags: Review Source Type: research

Management of Patients With Atrial Fibrillation by Primary‐Care Physicians in Germany: 1‐Year Results of the ATRIUM Registry
ConclusionsIn this unselected group of patients with long‐standing AF managed in primary care, hospitalizations and cardiovascular complications including strokes are frequent, illustrating the need to improve management of AF patients.
Source: Clinical Cardiology - March 1, 2014 Category: Cardiology Authors: Paulus Kirchhof, Janine Schmalowsky, David Pittrow, Ludger Rosin, Wilhelm Kirch, Karl Wegscheider, Thomas Meinertz, Tags: Quality and Outcomes Source Type: research

Antithrombotic Regimens for Patients Taking Oral Anticoagulation After Coronary Intervention: A Meta‐analysis of 16 Clinical Trials and 9185 Patients
This study sought to compare efficacy and safety outcomes of triple therapy (OAC, aspirin, and clopidogrel) vs dual therapy (clopidogrel with aspirin or OAC) in these patients. We hypothesize OAC plus clopidogrel could be the optimal regimen for patients with indications for OAC receiving stent implantation. Medline, the Cochrane Library, and other Internet sources were searched for clinical trials comparing the efficacy and safety of triple vs dual therapy for patients taking OAC after coronary stenting. Sixteen eligible trials including 9185 patients were identified. The risks of major adverse cardiac events (odds ratio ...
Source: Clinical Cardiology - May 12, 2015 Category: Cardiology Authors: Xiao‐Fei Gao, Yan Chen, Zhong‐Guo Fan, Xiao‐Min Jiang, Zhi‐Mei Wang, Bing Li, Wen‐Xing Mao, Jun‐Jie Zhang, Shao‐Liang Chen Tags: Reviews Source Type: research

Where There's Smoke, There's Fire? Significance of Atrial Fibrillation in Young Patients
ConclusionsAtrial fibrillation occurs in young patients with and without structural heart disease. Young AF patients without comorbidities rarely develop CVD during the first years after diagnosis. Yet, an SVT is found in a high proportion of young AF patients; AF may be first manifestation of SVT. Therefore, young patients should undergo further evaluation for SVT
Source: Clinical Cardiology - February 5, 2016 Category: Cardiology Authors: Alexander Wutzler, Sophie von Ulmenstein, Philipp Attanasio, Martin Huemer, Abdul Shokor Parwani, Katharina Völk, Florian Blaschke, Leif‐Hendrik Boldt, Wilhelm Haverkamp Tags: Clinical Investigations Source Type: research

Impact of Switching From a Vitamin K Antagonist to Rivaroxaban on Satisfaction With Anticoagulation Therapy: The XANTUS‐ACTS Substudy
ConclusionsWithin this XANTUS cohort, switching from a VKA to rivaroxaban yielded statistically and clinically significant improvements in ACT burden and benefit scores.
Source: Clinical Cardiology - June 29, 2016 Category: Cardiology Authors: Craig I. Coleman, Sylvia Haas, Alexander G.G. Turpie, Silvia Kuhls, Susanne Hess, Thomas Evers, Pierre Amarenco, Paulus Kirchhof, A. John Camm, Tags: Clinical Investigations Source Type: research

Direct oral anticoagulants in patients with atrial fibrillation and renal impairment, extremes in weight, or advanced age
A growing number of patients with an indication for stroke prevention in atrial fibrillation have kidney‐, age‐, or weight‐related alterations in pharmacokinetics that affect dosing of direct oral anticoagulants. Because these patients were excluded from or comprised a small number of patients in clinical trials, there is a lack of evidence to guide clinicians. As a consequence, many patients do not receive oral anticoagulation despite a high risk for atrial fibrillation–related stroke. Here, we present a review of direct oral anticoagulant pharmacokinetics and a review of the available clinical evidence in patient...
Source: Clinical Cardiology - October 6, 2016 Category: Cardiology Authors: Leo F. Buckley, Eva Rybak, Ahmed Aldemerdash, Judy W.M. Cheng, John Fanikos Tags: Review Source Type: research

Direct oral anticoagulant use in nonvalvular atrial fibrillation with valvular heart disease: a systematic review
In conclusion, subanalyses of DOAC landmark AF trials revealed that dabigatran, rivaroxaban, and apixaban may be safely used in AF patients with certain types of VHD: aortic stenosis, aortic regurgitation, and mitral regurgitation. More evidence is needed before routinely recommending these agents for patients with bioprosthetic valves or mild mitral stenosis. Patients with moderate to severe mitral stenosis or mechanical valves should continue to receive warfarin, as these patients were excluded from all landmark AF trials.
Source: Clinical Cardiology - December 21, 2016 Category: Cardiology Authors: Ryan E. Owens, Rajesh Kabra, Carrie S. Oliphant Tags: Reviews Source Type: research

Intracardiac echocardiography for verification for left atrial appendage thrombus presence detected by transesophageal echocardiography: the ActionICE II study
ConclusionsWith TEE, a false positive of an LAA thrombus may be indicated, especially when a thrombus is described as soft rather than solid. Our study suggests that ICE may be a valuable option for verification of a TEE‐based diagnosis of a thrombus.
Source: Clinical Cardiology - February 12, 2017 Category: Cardiology Authors: Jakub Baran, Beata Zaborska, Roman Piotrowski, Malgorzata Sikora ‐Frąc, Ewa Pilichowska‐Paszkiet, Piotr Kułakowski Tags: CLINICAL INVESTIGATIONS Source Type: research

Rationale and design of REDUCE ‐IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial
Residual cardiovascular risk persists despite statins, yet outcome studies of lipid‐targeted therapies beyond low‐density lipoprotein cholesterol (LDL‐C) have not demonstrated added benefit. Triglyceride elevation is an independent risk factor for cardiovascular events. High‐dose eicosapentaenoic acid (EPA) reduces triglyceride‐rich lipoproteins without raising LDL‐C. Omega‐3s have postulated pleiotropic cardioprotective benefits beyond triglyceride‐lowering. To date, no large, multinational, randomized clinical trial has proved that lowering triglycerides on top of statin therapy improves cardiovascular ou...
Source: Clinical Cardiology - March 14, 2017 Category: Cardiology Authors: Deepak L. Bhatt, Ph. Gabriel Steg, Eliot A. Brinton, Terry A. Jacobson, Michael Miller, Jean ‐Claude Tardif, Steven B. Ketchum, Ralph T. Doyle, Sabina A. Murphy, Paresh N. Soni, Rene A. Braeckman, Rebecca A. Juliano, Christie M. Ballantyne, Tags: TRIAL DESIGNS Source Type: research

Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction
Conclusions PAD increases the risk for adverse outcomes in HFpEF and is associated with HF rehospitalization. Practitioners should be aware of the inherent risk associated with PAD in HFpEF.
Source: Clinical Cardiology - April 26, 2017 Category: Cardiology Authors: Pratik B. Sandesara, Muhammad Hammadah, Ayman Samman ‐Tahhan, Heval M. Kelli, Wesley T. O'Neal Tags: CLINICAL INVESTIGATIONS Source Type: research

Oral anticoagulation management in patients with atrial fibrillation undergoing cardiac implantable electronic device implantation
ConclusionsManagement of anticoagulation among AF patients undergoing CIED implantation is highly variable, with OAC being interrupted in more than half of both warfarin‐ and NOAC‐treated patients. Bleeding and stroke events were infrequent in both warfarin and NOAC‐treated patients.
Source: Clinical Cardiology - May 1, 2017 Category: Cardiology Authors: Eric Black ‐Maier, Sunghee Kim, Benjamin A. Steinberg, Gregg C. Fonarow, James V. Freeman, Peter R. Kowey, Jack Ansell, Bernard J. Gersh, Kenneth W. Mahaffey, Gerald Naccarelli, Elaine M. Hylek, Alan S. Go, Eric D. Peterson, Jonathan P. Piccini, Tags: CLINICAL INVESTIGATIONS Source Type: research

Atrial fibrillation variability on long ‐term monitoring of implantable cardiac rhythm management devices
ConclusionsSignificant temporal variability in AF burden exists when measured continuously with an implantable CRMD.
Source: Clinical Cardiology - August 1, 2017 Category: Cardiology Authors: Rachel M. Kaplan, Paul D. Ziegler, Jodi Koehler, Taya V. Glotzer, Rod S. Passman Tags: CLINICAL INVESTIGATIONS Source Type: research